Neurophet Debuts Advanced AI Solution for Alzheimer's Treatment Monitoring at ASNR 2025

Neurophet, co-led by Jake Junkil Been and Donghyeon Kim, participated in the 63rd Annual Meeting of the American Society of Neuroradiology (ASNR 2025) held in Philadelphia, United States, from May 17 to 21, 2023. At this premier event, the company showcased its AI-driven solutions for diagnosing and treating brain disorders, with a particular focus on the clinical utility of 'Neurophet AQUA AD,' their specialized software for Alzheimer's disease. During the Industry Collaboration Session, Jake Junkil Been, one of Neurophet's co-CEOs, presented the key features and practical applications of Neurophet AQUA AD. This software leverages advanced algorithms to perform quantitative analysis of MRI and PET scans, assisting in the prescription, monitoring, and assessment of anti-amyloid antibody therapies for Alzheimer’s disease. These therapies, including the recently launched treatments Leqembi (lecanemab) and Kesunla (donanemab), have seen increased adoption due to ongoing clinical trials and the growing need for precise monitoring tools. ARIA (Amyloid-Related Imaging Abnormalities) is a critical concern in Alzheimer's treatment, as it can lead to serious side effects such as swelling or bleeding in the brain. Neurophet AQUA AD is particularly effective in detecting and monitoring ARIA, making it an invaluable resource for clinicians and researchers. The software's ability to provide detailed and accurate insights ensures that treatment efficacy can be assessed and any potential risks can be promptly addressed, enhancing patient safety and outcomes. Beyond the presentation, Neurophet also exhibited its suite of AI solutions at a booth during the conference. This included Neurophet AQUA, a platform for neurodegeneration imaging analysis, and Neurophet SCALE PET, which offers quantitative analysis for PET imaging. Additionally, the company displayed its brain imaging treatment planning software, Neurophet tES/TMS LAB, used for electric and magnetic brain stimulation, and its multiple sclerosis image analysis software, Neurophet AQUA MS. By attending ASNR 2025, Neurophet seeks to form strategic partnerships with global pharmaceutical companies and potential clients, further solidifying its position in the market. The company aims to collaborate with key opinion leaders (KOLs) in the field of neurology to promote the technological excellence and practical benefits of its products. Jake Junkil Been expressed confidence in the software's ability to meet the growing demand for precise monitoring of ARIA and other clinical needs, emphasizing the company's commitment to improving the lives of patients with brain disorders. The participation at ASNR 2025 reflects Neurophet's dedication to leveraging AI technology to advance the diagnosis and treatment of neurological conditions. Founded in 2016, the company has made significant strides in developing innovative solutions for brain disorders. Its flagship products, such as Neurophet AQUA AD, demonstrate the company's expertise in neuroscience and AI, positioning it as a leader in the field. Industry insiders see the introduction of Neurophet AQUA AD as a game-changer in Alzheimer's treatment monitoring. The software's precision and reliability in detecting ARIA are lauded, and its integration into clinical practices could streamline the evaluation process and improve patient care. Neurophem's proactive approach in showcasing its technology at major conferences like ASNR 2025 underscores its commitment to collaboration and innovation. Neurophet is committed to helping patients with brain disorders through continuous development and application of AI technology. The company's interdisciplinary expertise combines advanced computational methods with deep knowledge of neurological conditions, enabling the creation of cutting-edge diagnostic and therapeutic tools. As the global market for Alzheimer’s treatments expands, Neurophet's contributions are poised to play a crucial role in advancing patient care and research in the field.